Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection

Clinical and Diagnostic Laboratory Immunology

Volumn 5, Issue 5, 1998, Pages 597-603

  Fahey, John L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PATHOGENESIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0032435566     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.5.5.597-603.1998     Document Type: Short Survey

References (93)

1. Ascher, M. S., and H. W. Sheppard. 1990. AIDS as immune system activation. II. The panergic imnesia hypothesis. J. Acquired Immune Defic. Syndr. 3:177-191.
2. Aukrust, P., N. B. Liabakk, F. Müller, E. Lien, T. Espevik, and S. S. Froland. 1994. Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection. Correlations to clinical immunologic and virologic parameters. J. Infect. Dis. 169:420-424.
3. Bass, H. Z., D. W. Hardy, R. T. Mitsuyasu, J. M. Taylor, Y. X. Wang, M. A. Fischl, S. A. Spector, D. D. Richman, and J. L. Fahey. 1992. The effect of zidovudine treatment on serum neopterin and β2-microglobulin levels in mildly symptomatic human immunodeficiency virus type-1 (HIV-1) seropositive individuals. J. Acquired Immune Defic. Syndr. 5:215-221.
4. Bass, H. Z., J. L. Fahey, P. Nishanian, R. Detels, W. Cumberland, M. Kemeny, and S. Plaeger. 1997. Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes. Clin. Diagn. Lab. Immunol. 4:64-69.
5. Bass, H. Z., P. Nishanian, W. D. Hardy, R. T. Mitsuyasu, E. Esmail, W. Cumberland, and J. L. Fahey. 1992. Immune changes in HIV infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. Clin. Immunol. Immunopathol. 64:63-70.
6. Benito, J. M., J. M. Zabay, J. Gil, M. Bermejo, A. Escudero, E. Sanchez, and E. Fernandez Cruz. 1997. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR and CD25 antigens. J. Acquired Immune Defic. Syndr. 14:128-135.
7. Breen, E. C., J. F. Salazar-Gonzalez, L. P. Shen, J. A. Kolberg, M. S. Urdea, O. Martinez-Maza, and J. L. Fahey. 1997. Circulating CD8 T cells show increased interferon-γ mRNA expression in HIV infection. Cell. Immunol. 178:91-98.
8. Cao, Y., D. D. Ho, J. Todd, R. Kokka, M. Urdea, J. D. Lifson, M. Piatak, Jr., S. Chen, B. H. Hahn, and M. S. Saag. 1995. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res. Hum. Retroviruses 11:353-361.
9. Cardo, D. M., D. H. Culver, C. A. Ciesielski, P. U. Srivastava, R. Marcus, D. Abiteboul, J. Heptonstall, G. Ippolito, F. Lot, and P. S. McKibben. 1997. A case-control study of HIV seroconversion in health care workers after precutaneous exposure. N. Engl. J. Med. 337:1485-1490.
10. Centers for Disease Control. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid. Mortal. Weekly Rep. 41:961.
11. Choi, S., S. W. Lagakos, R. T. Schooley, and P. A. Volberding. 1993. CD4 lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann. Intern. Med. 118:674-680.
12. Clerici, M., J. V. Giorgi, C. C. Chou, V. K. Gudeman, J. A. Zack, P. Gupta, H. N. Ho, P. G. Nishanian, J. A. Berzofsky, and G. M. Shearer. 1992. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J. Infect. Dis. 165:1012-1019.
13. Clerici, M., and G. M. Shearer. 1993. A Th1 and Th2 switch is a critical step in the etiology of HIV infection. Immunol. Today 14:107-111.
14. Clerici, M., N. Stocks, R. A. Zajac, R. N. Boswell, D. R. Lucey, C. S. Via, and G. M. Shearer. 1989. Detection of three different patterns of T helper cell dysfunction in asymptomatic human HIV+ patients. J. Clin. Investig. 84: 1892-1899.
15. Cocchi, F., A. DeVico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1α and MIP-1β as the major HIV suppressive factor produced by CD8+ T cells. Science 270:1811-1815.
16. Cohen, O. J., A. Kinter, and A. S. Fauci. 1997. Host factors in the pathogenesis of HIV disease. Immunol. Rev. 159:31-48.
17. Coombs, R. W., A. C. Collier, J. P. Allain, B. Nikora, M. Leuther, G. F. Gjerset, and L. Corey. 1989. Plasma viremia in human immunodeficiency virus infection. N. Engl. J. Med. 321:1626-1631.
18. Crocchiolo, P. R., A. Lizioli, D. R. Bedarida, and M. P. Panzeri. 1988. CD4:neopterin ratio significantly improves correlation with the Walter Reed staging system if compared with CD4 and neopterin levels separately. AIDS 2:481-486.
19. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, and E. Gomperts. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by deletion allele of the CKR-5 structural gene. Science 273:1856-1862.
20. Deng, H., R. Liu, W. Ellmeier, S. Chou, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, and C. M. Hill. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
21. Emilie, D., R. Fior, L. Llorente, A. Marfaing-Koka, M. Peuchmaur, O. Devergne, B. Jarrousse, J. Wijdenes, F. Boue, and P. Galanaud. 1994. Cytokines from lymphoid organs of HIV-intected patients: production and role in the immune dysequilibrium of the disease. Immunol. Rev. 140:5-34.
22. Fahey, J. L., J. M. G. Taylor, and R. Detels. 1993. Is there a better index of HIV disease status than just CD4 T cell levels? In Proceedings of the IXIb International Conference on AIDS, Berlin, Germany.
23. Fahey, J. L., J. M. G. Taylor, R. Detels, B. Hofmann, R. Melmed, P. Nishanian, and J. V. Giorgi. 1990. The prognostic value of cellular and serologic markers in HIV infection. N. Engl. J. Med. 322:166-172.
24. Fahey, J. L., J. M. G. Taylor, E. Kozns, and P. Nishanian. 1986. Diagnostic and prognostic factors in AIDS. Mt. Sinai J. Med. 53:657-663.
25. Fahey, J. L., J. M. G. Taylor, B. Manna, P. Nishanian, N. Aziz, J. V. Giorgi, and R. Detels. Prognostic significance of plasma markers of immune activation. HIV viral load and CD4 T cell measurements. AIDS, in press.
26. Fan, J., H. Z. Bass, and J. L. Fahey. 1993. Elevated IFNγ and decreased IL-2 expression are associated with HIV infection. J. Immunol. 151:5031-5037.
27. Fauci, A. S. 1993. Multifactorial nature of HIV disease: implications for therapy. Science 262:1011-1018.
28. Fay, S. P., B. Barnett, V. Granger, and T. Mercolino. 1994. Absolute control-full-process leukocyte immunophenotyping quality control using a stabilized whole blood preparation. Cytom. Commun. Clin. Cytom. 18(3):177.
29. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane domain, G. protein coupled receptor. Science 272:872-877.
30. Fuchs, D., H. Jager, M. Popescu, G. Reibnegger, E. R. Werner, M. P. Dierich, W. Kaboth, G. P. Tilz, and H. Wachter. 1990. Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol. Lett. 26:75-80.
31. Fuchs, D., A. Hausen, G. Reibnegger, E. R. Werner, M. P. Dierich, and H. Wachter. 1988. Neopterin as a marker for activated cell mediated immunity, application to HIV infection. Immunol. Today 9:150-155.
32. Giorgi, J. V. 1993. Characterization of T lymphocyte subset alterations by flow cytometry in HIV disease. Ann. N. Y. Acad. Sci. 677:126-137.
33. Giorgi, J. V., H. N. Ho, K. Hirji, C. C. Chou, L. E. Hultin, S. O'Rourke, L. Park, J. B. Margolick, J. Ferbas, and J. P. Phair. 1994. CD8+ lymphocyte activation of HIV type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. J. Infect. Dis. 170:775-781.
34. Giorgi, J. V., Z. Liu, L. E. Hultin, W. G. Cumberland, K. Hennessey, and R. Detels. 1993. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J. Acquired Immune Defic. Syndr. 6:904-912.
35. Godfried, M. H., T. van der Poll, G. J. Weverling, J. W. Mulder, J. Jansen, S. J. H. van Deventer, and H. P. Sauerwein. 1994. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J. Infect. Dis. 169:739-745.
36. Gordon, J., L. Flores-Romo, J. A. Cairns, M. J. Millsum, P. J. Lane, G. D. Johnson, and I. C. MacLennan. 1989. CD23: a multi-functional receptor lymphokine? Immunol. Today 10:153-157.
37. Graham, N. M. H. 1996. The role of immunologic and viral markers in predicting clinical outcome in HIV infection. AIDS 10:S21-S25.
38. Graziosi, G., G. Pantaleo, K. R. Gantt, J. P. Fortin, J. F. Demarest, O. J. Cohen, R. P. Sekaly, and A. S. Fauci. 1994. Lack of evidence for the dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 265:248-252.
39. Hofmann, B., H. Bass, P. Nishanian, M. Faisal, R. A. Figlin, G. P. Sarna, and J. L. Fahey. 1992. Different lymphoid cell populations produce varied levels of neopterin, beta-2 microglobulin and sIL-2R when stimulated with IL-2, IFNγ and TNFα. Clin. Exp. Immunol. 88:548-554.
40. Hofmann, B., I. Bygbjerg, E. Dickmeiss, V. Faber, B. Frederiksen, J. Gaub, J. Gerstoft, B. K. Jakobsen, K. D. Jacobsen, and B. O. Lindharadt. 1989. Prognostic value of immunologic abnormalities and HIV antigenemia in asymptomatic HIV-infected individuals: proposal for immunologic staging. Scand. J. Infect. Dis. 21:633-643.
41. Hofmann, B., P. Nishanian, J. L. Fahey, I. Esmail, A. L. Jackson, R. Detels, and W. Cumberland. 1991. Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV-1 infection: distinctive parameters of HIV-1 induced changes. Clin. Immunol. Immunopathol. 61:212-224.
42. Hofmann, B., Y. Wang, W. G. Cumberland, R. Detels, M. Bozorgmehri, and J. L. Fahey. 1990. Serum β2M level increases in HIV infection: relation to seroconversion, CD4 T cell fall and prognosis. AIDS 4:207-214.
43. Homburger, H. A., W. Rosenstock, H. Paxton, M. L. Paton, and A. L. Landay. 1993. Assessment of interlaboratory variability of immunophenotyping. Results of the College of American Pathologists survey. Ann. N. Y. Acad. Sci. 677:43-49.
44. Homsy, I., M. Meyer, and J. A. Levy. 1990. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol. 64:1437-1440.
45. Huber, C., J. R. Batchelor, D. Fuchs, A. Hausen, A. Lang, D. Niederwieser, G. Reibnegger, P. Swetly, J. Troppmair, and H. Wachter. 1984. Immune response-associated production of neopterin. Release from macrophages is primarily under control of interferon-gamma. J. Exp. Med. 160:310-316.
46. Jurriaans, S., B. Van Gemen, G. J. Weverling, D. Van Strijp, P. Nara, R. Coutinho, M. Koot, H. Schuitemaker, and Y. Goudsmit. 1994. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 204:223-233.
47. Koot, M., J. P. M. Keet, A. H. V. Vos, R. E. de Goede, M. T. Roos, R. A. Coutinho, F. Miedema, P. T. Schellekens, and M. Tersmette. 1993. Prognostic value of HIV-1 biological phenotype for rate of CD4 cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688.
48. Kovacs, J. A., S. Vogel, J. M. Albert, J. Falloon, R. T. Davey, R. E. Walker, M. A. Polis, K. Spooner, J. A. Metcalf, and M. Baseler. 1996. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335:1350-1356.
49. Kramer, A., R. J. Biggar, H. Hampl, R. M. Friedman, D. Fuchs, H. Wachter, and J. J. Goedert. 1992. Immunological markers of progression to AIDS are time-dependent and illness-specific. Am. J. Epidemiol. 136:71-80.
50. Lane, H. C., J. M. Depper, W. C. Greene, G. Whalen, T. A. Waldmann, and A. S. Fauci. 1985. Qualitative analysis of immune function in patients with acquired immune deficiency syndrome. N. Engl. J. Med. 313:79-84.
51. Liu, M., J. L. Fahey, N. Aziz, W. G. Cumberland, G. Skowron, and T. Merigan. 1994. Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. J. Infect. Dis. 170:1165-1171.
52. Liu, Z., W. G. Cumberland, L. E. Hultin, H. E. Prince, R. Detels, and J. V. Giorgi. 1997. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquired Immune Defic. Syndr. 16:83-92.
53. Lyamuya, E. F., C. Kagona, E. C. Mbena, W. K. Urassa, K. Pallangyo, F. S. Mhalu, and G. Biberfeld. 1996. Evaluation of the FACScount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination. J. Immunol. Methods 195:103-112.
54. Marinkovic, S., G. P. Jahreis, G. G. Wong, and H. Baumann. 1989 IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J. Immunol. 142:808-812.
55. Mellors, J. W., A. Muñoz, J. V. Giorgi, J. B. Margolick, C. J. Tassoni, P. Gupta, L. A. Kingsley, J. A. Todd, A. J. Saah, R. Detels, J. P. Phair, and C. R. Rinaldo, Jr. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:946-954.
56. Melmed, R. N., J. M. G. Taylor, R. Detels, M. Bozorgmehri, and J. L. Fahey. 1989. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J. Acquired Immune Defic. Syndr. 2:70-76.
57. Miedema, F., L. Meyaard, M. Koot, M. R. Klein, M. T. Roos, M. Groenink, R. A. Fouchier, A. B. Van't Wout, M. Tersmette, and P. T. Schellekens. 1994. Changing virus-host interactions in the course of HIV infection. Immunol. Rev. 140:35-72.
58. Mildvan, D., A. Landay, V. DeGruttola, S. G. Machado, and J. Kagan. 1997. An approach to the validation of markers for use in AIDS clinical trials. Clin. Infect. Dis. 24:764-774.
59. Miles, S., O. Martinez-Maza, A. Rezai, L. Magpantay, T. Kishimoto, S. Nakamura, S. F. Radka, and P. S. Linsley. 1992. Oncostatin M as a potent mitogen for AIDS Kaposi sarcoma cells. Science 255:1432-1434.
60. Moss, A. R., P. Bacchetti, D. Osmond, W. Krampf, R. E. Chaisson, D. Stites, J. Wilber, J. P. Alain, and J. Carlson. 1988. Seropositivity for HIV and development of AIDS: 3 year follow up. Br. Med. J. 296:745-750.
61. Murray, H. W., B. V. Rubin, H. Masur, and R. B. Roberts. 1984. Impaired production of lymphokines and immune (gamma) interferon in the acquired immune deficiency syndrome. N. Engl. J. Med. 310:883-889.
62. Nishanian, P., B. Hofmann, Y. Wang, A. L. Jackson, R. Detels, and J. L. Fahey. 1991. Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease. AIDS 5:805-812.
63. Nishanian, P., R. Huskins, S. Stehn, R. Detels, and J. L. Fahey. 1990. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J. Infect. Dis. 162:21-28.
64. Osmond, D. H., S. Shiboski, P. Bacchetti, E. E. Winger, and A. R. Moss. 1991. Immune activation markers and AIDS prognosis. AIDS 5:505-511.
65. Pal, R., A. Garzino-Demo, P. D. Markham, J. Burns, M. Brown, R. C. Gallo, and A. L. DeVico. 1997. Inhibition of HIV-1 infection by the β-chemokine MDC. Science 278:695-698.
66. Pantaleo, C., and A. S. Fauci. 1995. New concepts in the immunopathogenesis of HIV infection. Annu. Rev. Immunol. 15:487-512.
67. Peddecord, K. M., A. S. Berenson, L. K. Hofherr, D. P. Francis, R. S. Garfein, G. D. Cross, and W. O. Schalla. 1993. Variability of reporting and lack of adherence to consensus guidelines in human T-lymphocyte immunophenotyping reports. J. Acquired Immune Defie. Syndr. 6:823-830.
68. Phair, J., A. Muñoz, R. Detels, R. Kaslow, C. Rinaldo, and A. Saah. 1990. The risk of pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N. Engl. J. Med. 322:161-165.
69. Piatak, M., Jr., M. Saag, L. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma at all stages of infection determined by competitive PCR. Science 259:1749-1754.
70. Pilgrim, A. K., G. Pantaleo, O. J. Cohen, L. M. Fink, J. Y. Zhou, D. P. Bolognesi, A. S. Fauci, and D. C. Montefiori. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term nonprogressive infection. J. Infect. Dis. 176:924-932.
71. Plaeger, S., H. Z. Bass, P. Nishanian, J. Thomas, N. Aziz, R. Detels, J. King, W. Cumberland, M. Kemeny, and J. L. Fahey. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation markers changes. Clin. Immunol. Immunopathol., in press.
72. Rabin, R. L., M. Roederer, Y. Maldonado, A. Petru, and L. A. Herzenberg. 1995. Altered representation of naive and memory CDS T cell subsets in HIV infected children. J. Clin. Investig. 95:2054-2060.
73. Richman, D. D. 1996. Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Adv. Exp. Med. Biol. 394:383-395.
74. Richman, D. D., and S. A. Bozzette. 1994. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169:968-974.
75. Rinaldo, C. R., L. A. Beltz, X. L. Huang, P. Gupta, Z. Fan, and D. J. Torpey. 1995. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res. Hum. Retrovirusus 11:481-489.
76. Romagnani, S., G. del Prete, R. Manetti, A. Ravina, F. Annunziato, M. De Carli, M. Mazzetti, M. P. Piccini, M. M. D'Elios, and P. Parronchi. 1994. Role of Th1/Th2 cytokines in HIV infection. Immunol. Rev. 140:73-92.
77. Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, and T. Corrah. 1995. HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64.
78. Salazar-Gonzalez, J. F., O. Martinez-Maza, N. Aziz, J. A. Kolberg, T. Yeghiazarian, L. P. Shen, and J. L. Fahey. 1997. Relationship of plasma HIV-RNA levels and levels of TNFα and immune activation products in HIV infection. Clin. Immunol. Immunopathol. 84:36-45.
79. Sarna, G., H. Machleder, J. Collins, B. Bonavida, E. Jacobs, R. Hawkins, S. Golub, H. Shau, J. L. Fahey, and J. Popow. 1994. A comparative study of intravenous versus intralymphatic interleukin-2 with assessment of effects of interleukin-2 on both peripheral blood and thoracic-duct lymph. J. Immunother. 15:140-146.
80. Schroff, R. H., M. S. Gottlieb, H. E. Prince, L. L. Chai, and J. L. Fahey. 1983. Immunological studies of homosexual men with immunodeficiency and Kaposi's sarcoma. Clin. Immunol. Immunopathol. 27:308-314.
81. Sheppard, H. W., M. S. Ascher, B. McRae, R. E. Anderson, W. Lang, and J. P. Allain. 1991. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J. Acquired Immune Defic. Syndr. 4:704-712.
82. Smith, K., and D. A. Cantrell. 1995. IL-2 regulates its own receptors. Proc. Natl. Acad. Sci. USA 82:864-868.
83. Strickler, H. D., J. F. Blanchard, D. Vlahov, E. Taylor, A. Munoz, K. E. Nelson, and J. B. Margolick. 1993. Elevated serum levels of neopterin but not beta 2-microglobulin in HIV-1 seronegative injecting drug users. AIDS 7:361-367.
84. Tsoukas, C. M., and N. F. Bernard. 1994. Markers predicting progression of HIV-related disease. Clin. Microbiol. Rev. 7:14-28.
85. Valentine, F. T., and M. A. Jacobson. 1990. Immunological and virological surrogate markers in the evaluation of therapies for HIV infection. AIDS 405:201-207.
86. Vanham, G., K. Edmonds, L. Qing, D. Horn, Z. Toossi, B. Jones, C. L. Daley, B. Huebner, L. Kestens, and P. Gigase. 1996. Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clin. Exp. Immunol. 103:30-34.
87. Walker, B. D., S. Chakrabarti, M. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. 1987. HIV-specific cytotoxic lymphocytes in seropositive individuals. Nature 328:345-348.
88. Walker, C. M., D. J. Moody, D. P. Stites, and J. A. Levy. 1986. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563-1566.
89. Watchi, R., E. R. Stiehm, J. L. Fahey, M. Stone, A. Deveikis, L. Frenkel, G. Aldrovandi, S. O'Rourke, L. Wei, and Y. J. Bryson. 1994. Neopterin is a better predictor of disease severity than b2M in pediatric HIV infection. Pediatr. AIDS HIV Infect. Fetus Adolesc. 5(4):226-231.
90. Yametz, S., W. G. Cumberland, M. van der Meyden, and O. Martinez-Maza. 1995. Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma. Blood 85:1843-1849.
91. Yarchoan, R., D. J. Venzon, J. M. Pluda, J. Lietzau, K. M. Wyvill, A. A. Tsiatis, S. M. Steinberg, and S. Broder. 1991. CD4 counts and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann. Intern. Med. 115:184-189.
92. Zangerle, R., D. Fuchs, G. Reibnegger, P. Fritsch, and H. Wachter. 1991. Markers for disease progression in intravenous drug users infected with HIV-1. AIDS 5:985-991.
93. Zangerle, R., H. Gallati, M. Sarcletti, G. Weiss, H. Denz, H. Wachter, and D. Fuchs. 1994. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV infected individuals are associated with immune activation. J. Acquired Immune Defic. Syndr. 7:79-85.